DK2533791T3 - Leucin-peptid-sammensætning og fremgangsmåde til formulering - Google Patents
Leucin-peptid-sammensætning og fremgangsmåde til formulering Download PDFInfo
- Publication number
- DK2533791T3 DK2533791T3 DK10842737.8T DK10842737T DK2533791T3 DK 2533791 T3 DK2533791 T3 DK 2533791T3 DK 10842737 T DK10842737 T DK 10842737T DK 2533791 T3 DK2533791 T3 DK 2533791T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino acid
- protein
- composition
- suspension
- approx
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 58
- 238000000034 method Methods 0.000 title claims description 37
- 238000009472 formulation Methods 0.000 title description 3
- 150000001413 amino acids Chemical class 0.000 claims description 89
- 235000018102 proteins Nutrition 0.000 claims description 57
- 102000004169 proteins and genes Human genes 0.000 claims description 57
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 239000000725 suspension Substances 0.000 claims description 37
- 239000007787 solid Substances 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108010046377 Whey Proteins Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 102000007544 Whey Proteins Human genes 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 235000021119 whey protein Nutrition 0.000 claims description 11
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims 8
- 230000000593 degrading effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 62
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 32
- 229960003136 leucine Drugs 0.000 description 27
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 22
- 239000000047 product Substances 0.000 description 13
- -1 for example Chemical class 0.000 description 6
- 239000004395 L-leucine Substances 0.000 description 5
- 235000019454 L-leucine Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 229960003121 arginine Drugs 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 150000005693 branched-chain amino acids Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000013530 defoamer Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 229940116886 human interleukin-6 Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dispersion Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Fremgangsmåde til fremstilling af en aminosyresammensætning med forøget opløselighed, hvilken fremgangsmåde omfatter blanding af mindst én mikroniseret aminosyre, der omfatter mindst ca. 90 procent partikler på mindre end ca. 160 mikrometer, med mindst ét protein til fremstilling af en faststofblanding, der omfatter aminosyren og proteinet, suspendering af faststofblandingen til dannelse af en i det væsentlige homogen vandig suspension og tørring af suspensionen til fremstilling af et aminosyre-protein-produkt.
2. Fremgangsmåde ifølge krav 1, hvor den mikroniserede aminosyre har en partikelstørrelse på fra ca. 7 til ca. 10 mikrometer.
3. Fremgangsmåde ifølge krav 1, hvor aminosyren er en hydrofob aminosyre.
4. Fremgangsmåde ifølge krav 1, hvor aminosyren er en forgrenet aminosyre.
5. Fremgangsmåde ifølge krav 1, hvor proteinet omfatter peptider, som er afledt af valleprotein.
6. Fremgangsmåde ifølge krav 1, hvor faststofblandingen omfatter fra ca. 7 til ca. 55 procent af suspensionen.
7. Fremgangsmåde ifølge krav 1, hvor aminosyren omfatter fra ca. 5 til ca. 90 procent af faststofblandingen.
8. Aminosyresammensætning med forbedret opløselighed for mindst én aminosyre, hvor sammensætningen fremstilles ved en fremgangsmåde, der omfatter coprocessering af en blanding, der omfatter mindst én mikroniseret aminosyre, der omfatter mindst ca. 90 procent partikler på mindre end ca. 160 mikrometer, og mindst ét protein til fremstilling af en i det væsentlige homogen vandig suspension; og tørring af suspensionen til opnåelse af et i det væsentlige fast og/eller pulverformigt peptid-aminosyre-produkt.
9. Aminosyresammensætning ifølge krav 8, hvor den mikroniserede aminosyre har en partikelstørrelse på fra ca. 7 til ca. 10 mikrometer.
10. Aminosyresammensætning ifølge krav 8, hvor aminosyren er en hydrofob aminosyre.
11. Aminosyresammensætning ifølge krav 8, hvor aminosyren er en forgrenet aminosyre.
12. Aminosyresammensætning ifølge krav 8, hvor proteinet omfatter peptider, som er afledt af valleprotein.
13. Aminosyresammensætning ifølge krav 8, hvor faststofblandingen omfatter fra ca. 7 til ca. 55 procent af suspensionen
14. Aminosyresammensætning ifølge krav 8, hvor aminosyren omfatter fra ca. 5 til ca. 90 procent af faststofblandingen.
15. Fremgangsmåde til forringelse af viskositeten afen proteinsammensætning, hvilken fremgangsmåde omfatter blanding af mindst én aminosyre, der omfatter mindst ca. 90 procent partikler på mindre end ca. 160 mikrometer, med mindst ét protein til fremstilling af en faststofblanding, der omfatter aminosyren og proteinet, suspendering af faststofblandingen i en i det væsentlige homogen vandig suspension og tørring af suspensionen til fremstilling af en proteinsammensætning, der er mindre viskøs ved rekonstituering i vandige sammensætninger.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28876709P | 2009-12-21 | 2009-12-21 | |
| PCT/US2010/061624 WO2011084816A1 (en) | 2009-12-21 | 2010-12-21 | Leucine/peptide composition and method of formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2533791T3 true DK2533791T3 (da) | 2017-05-08 |
Family
ID=44305747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10842737.8T DK2533791T3 (da) | 2009-12-21 | 2010-12-21 | Leucin-peptid-sammensætning og fremgangsmåde til formulering |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20110233469A1 (da) |
| EP (1) | EP2533791B1 (da) |
| DK (1) | DK2533791T3 (da) |
| ES (1) | ES2625331T3 (da) |
| PL (1) | PL2533791T3 (da) |
| WO (1) | WO2011084816A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2945489B1 (en) * | 2013-01-15 | 2023-03-08 | Glanbia Nutritionals Limited | Method for improving viscosity, solubility, and particle size of milk protein concentrates |
| AU2014225786B2 (en) | 2013-03-08 | 2017-10-12 | Axiom Foods, Inc. | Rice protein supplements |
| KR20170080579A (ko) | 2014-10-01 | 2017-07-10 | 플랜트 헬스 케어, 인코포레이티드 | 파괴된 과민성 반응 박스를 갖는 유발제 펩티드 및 그의 용도 |
| JP2017530197A (ja) | 2014-10-01 | 2017-10-12 | プラント ヘルス ケア インコーポレイテッド | 過敏感反応エリシターペプチド及びその使用 |
| US10188135B2 (en) | 2015-11-04 | 2019-01-29 | Stokley-Van Camp, Inc. | Method for inducing satiety |
| WO2017176588A1 (en) | 2016-04-06 | 2017-10-12 | Plant Health Care, Inc. | Beneficial microbes for delivery of effector peptides or proteins and use thereof |
| PL3439682T3 (pl) | 2016-04-06 | 2025-12-01 | Plant Health Care, Inc. | Peptydy pochodzące od czynnika wywołującego odpowiedź nadwrażliwości i ich stosowanie |
| CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4091120A (en) * | 1976-11-15 | 1978-05-23 | Mead Johnson & Company | Liquid dietary product containing soy protein membrane isolate |
| US6528067B1 (en) * | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| WO2000000221A1 (en) * | 1998-06-26 | 2000-01-06 | Otsuka Pharmaceutical Co., Ltd. | Water soluble dry compositions |
| DE60025019T2 (de) * | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
| ATE307144T1 (de) * | 2000-05-22 | 2005-11-15 | Univ Ramot | Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen |
| US20070128252A1 (en) * | 2002-03-01 | 2007-06-07 | Glanbia Nutritionals (Ireland) Limited | Compositions and methods for treatment of body weight conditions |
| JP4970694B2 (ja) * | 2002-12-02 | 2012-07-11 | 株式会社明治 | 持続性筋肉疲労改善剤 |
| MXPA05011784A (es) * | 2003-05-05 | 2006-01-26 | Unilever Nv | Producto de caseina hidrolizada que comprende tripeptidos isoleucina-prolina-prolina y/o valina-prolina-prolina. |
| WO2007095716A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
| US20090042770A1 (en) * | 2007-01-14 | 2009-02-12 | Bastian Eric D | Branched Chain Amino Acid Chelate |
| US20090203789A1 (en) * | 2008-01-31 | 2009-08-13 | Multi Formulations Ltd. | Fast Dissolution Amino Acid Composition |
| US20090264363A1 (en) * | 2008-03-26 | 2009-10-22 | Ward Loren S | Leucine-Rich Peptide Compositions and Methods for Isolation |
| US20100209558A1 (en) * | 2009-02-19 | 2010-08-19 | General Nutrition Corporation | Dietary ingredient with enhanced bioavailability |
-
2010
- 2010-12-21 DK DK10842737.8T patent/DK2533791T3/da active
- 2010-12-21 ES ES10842737.8T patent/ES2625331T3/es active Active
- 2010-12-21 PL PL10842737T patent/PL2533791T3/pl unknown
- 2010-12-21 WO PCT/US2010/061624 patent/WO2011084816A1/en not_active Ceased
- 2010-12-21 US US12/975,179 patent/US20110233469A1/en not_active Abandoned
- 2010-12-21 EP EP10842737.8A patent/EP2533791B1/en not_active Not-in-force
-
2021
- 2021-03-04 US US17/192,818 patent/US20210401743A1/en not_active Abandoned
- 2021-09-16 US US17/477,458 patent/US20220016027A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2533791B1 (en) | 2017-01-25 |
| PL2533791T3 (pl) | 2017-10-31 |
| US20110233469A1 (en) | 2011-09-29 |
| WO2011084816A1 (en) | 2011-07-14 |
| US20220016027A1 (en) | 2022-01-20 |
| ES2625331T3 (es) | 2017-07-19 |
| US20210401743A1 (en) | 2021-12-30 |
| EP2533791A1 (en) | 2012-12-19 |
| EP2533791A4 (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210401743A1 (en) | Leucine/Peptide Composition and Method of Formulation | |
| JP7537568B2 (ja) | 水中油型ピッカリングエマルション | |
| Wang et al. | Nanoparticles prepared by proso millet protein as novel curcumin delivery system | |
| JP5871910B2 (ja) | 植物タンパク質のアルカリ加水分解物を調製する方法 | |
| JP5461349B2 (ja) | ポリフェノール含有タンパク質の製造方法 | |
| JP2024003151A (ja) | 微小被包化した生成物、その透明な溶液、および作製法 | |
| US12357011B2 (en) | Treatment of bran from the seeds of black mustard or brown indian mustard and use of the treated bran in food products | |
| Samarathunga et al. | Formulation and characterization of hybrid milk containing bovine and Spirulina proteins | |
| KR102074537B1 (ko) | 수용성 활성 성분을 포함하는 나노겔 | |
| JP7321167B2 (ja) | 保存安定性の窒素含有有機酸組成物 | |
| US9445622B2 (en) | Compositions and methods for improving creatine solubility and stability | |
| LÜ et al. | Stability and in vitro digestion of pectin-walnut proteins stabilized emulsions encapsulating curcumin | |
| JP7285310B2 (ja) | 乳由来タンパク質含有顆粒状組成物、その製造方法及び乳由来タンパク質含有顆粒状組成物の分散性を改善する方法 | |
| JPWO1999062935A1 (ja) | カルボン酸とアミノ酸又はアミノ酸縮合体反応物及びその製造方法 | |
| CN107853676A (zh) | 一种复合蛋白聚集体颗粒起泡剂及其制备方法 | |
| JP2017038574A (ja) | 水中油型乳化物 | |
| WO2026023693A1 (ja) | 乳化組成物、その製造方法、並びに乳化組成物を含む食品、乳代替物、医薬品、化粧品及びパーソナルケア製品 | |
| WO2026023673A1 (ja) | 水中油型乳化組成物、水中油型乳化組成物の製造方法、微粒子乳化剤、食品、乳代替物、医薬品、化粧品及びパーソナルケア製品 | |
| WO2023191026A1 (ja) | タンパク質、該タンパク質を含むタンパク質粒子分散液及び乳化組成物、並びにこれらの製造方法 | |
| Chaiwong et al. | Journal of Agriculture and Food Research | |
| HK40045260A (en) | Oil-in-water pickling emulsion | |
| JP2008271794A (ja) | 複合体及びその製造方法、並びにそれを含有する食品 | |
| JP2007259826A (ja) | 粉末状或いは顆粒状のスープ又はソース |